← The record

Seladelpar

Recommended HepatologyAuthority RequiredSecond-line line 💬 consumer voice

Treatment of primary biliary cholangitis in patients with inadequate response to ursodeoxycholic acid (UDCA) or intolerance to UDCA.

2
Submissions
2025–25
On the record
Redacted
ICER range
commercial-in-confidence
Redacted
Cost basis
risk sharing

Decisions on record

2 decisions
  • Meeting Dec 2025 Recommended Primary biliary cholangitis (PBC) no PSD
  • Meeting Jul 2025 Deferred Primary biliary cholangitis inadequately responsive to or intolerant to ursodeoxycholic acid

Access path

2 submissions · public record
  1. Dec 2025
    Recommended · restricted

    vs best supportive care, obeticholic acid, elafibranor

  2. Dec 2025
    Recommended · restricted
  3. PBS listing · Authority Required
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
7.1 The PBAC deferred making a recommendation for the listing of seladelpar for the treatment of primary biliary cholangitis (PBC). The PBAC was of a mind to recommend seladelpar, pending advice from the TGA Delegate. The PBAC considered that seladelpar was non-inferior in terms of effectiveness and safety compared to obeticholic acid (OCA) and therefore, considered that a cost-minimisation approach versus OCA was appropriate.PSD · Jul 2025
7.2 The PBAC acknowledged the input from the Liver Foundation supporting the submission. The PBAC also noted the input provided during the Sponsor hearing, which highlighted the need for alternative treatments for patients who do not respond to first-line treatment with ursodeoxycholic acid (UDCA).PSD · Jul 2025
Economic analysis
6.57 The submission presented cost utility analyses comparing seladelpar ± UDCA with BSC ± UDCA and OCA ± UDCA. Given that (i) the ESC considered that seladelpar was non- inferior compared to both OCA and elafibranor in terms of efficacy and safety, (ii) elafibranor was recommended by the PBAC in March 2025 on the basis of a cost- minimisation approach versus OCA (see paragraph 2.2) and (iii) elafibranor was not yet listed on the PBS, the ESC considered …PSD · Jul 2025
The ESC considered that a similar approach could be applied to the cost minimisation between seladelpar and OCA. Cost utility analysis versus BSC (± UDCA) and OCA (± UDCA)PSD · Jul 2025
Clinical claim
Table 2: Trials and associated reports presented in the submission Trial ID Protocol title/ Publication title Publication citation Seladelpar RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to RESPONSE Evaluate the Efficacy and Safety of Seladelpar in Patients with PrimaryPSD · Jul 2025
30 November 2023 NCT04620733 Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) Hirschfield GM, Bowlus CL, Mayo MJ, et al. A Phase 3 Trial of Seladelpar NEJM. 2024; 390(9):783-94 in Primary Biliary Cholangitis OCA POISE NCT01473524 Nevens F, Andreone P, Mazzella G, et al. A Placebo-controlled trial of NEJM. 2016; 375(7):631- EUCTR2011- obeticholic acid in primary biliary cholangitis. 43.PSD · Jul 2025
Consumer comments
6.3 The PBAC noted and welcomed the input from one organisation, the Liver Foundation via the Consumer Comments facility on the PBS website. The comment supported the listing of seladelpar on the PBS.PSD · Jul 2025
6.4 The comments described the significant impact of PBC on quality of life, particularly chronic fatigue and severe itching, which can be debilitating, relentless and indescribable, with no effective relief.PSD · Jul 2025

Cost-effectiveness

The submission proposed a placeholder DPMQ with no published or effective price for seladelpar. The ICER was deliberately overestimated due to confidential special pricing arrangements for the comparator (OCA).

The PBAC considered that a price premium for elafibranor would be reasonable given the potential reduction in PBC-related pruritus compared to OCA. PBAC · 2025
ICER uncertain ×2Surrogate endpointCost-effectiveness accepted

Decision context

PopulationPatients aged 18 years or older with primary biliary cholangitis who have had an inadequate response to UDCA (despite at least 52 weeks of treatment) or are intolerant to UDCA, and have elevated ALP (≥1.67x ULN) or elevated total bilirubin (1-2x ULN).

Risk sharingThe PBAC considered that seladelpar should join the risk sharing arrangement for OCA.

Submission history

2 entries
DecidedOutcomeComparatorICEREvidence
Dec 2025 Recommended · restricted best supportive care, obeticholic acid, elafibranor RCT · Surrogate
Dec 2025 Recommended · restricted best supportive care, obeticholic acid, elafibranor RCT · Surrogate

Consumer voice

Dec 2025

The Liver Foundation submitted consumer input supporting PBS listing of seladelpar, highlighting the significant impact of PBC on quality of life, particularly chronic fatigue and severe itching that can be debilitating and relentless with no effective relief.

The comments described the significant impact of PBC on quality of life, particularly chronic fatigue and severe itching, which can be debilitating, relentless and indescribable, with no effective relief. Consumer comments · PSD
quality of lifeunmet needtreatment burdensymptom severity

Similar precedents

By decision profile

Regulatory · TGA

Label narrower than PBS population — PBAC restricts to inadequate response or intolerance to UDCA after ≥52 weeks; TGA label includes all primary biliary cholangitis patients.